INBIOGEN Files Governance Report: Director Appointments Rejected and Multiple Non-Compliance Issues Highlight Governance Risks
INBIOGEN disclosed its corporate governance report, failing to comply with 10 out of 15 key indicators, revealing governance weaknesses.
At the 18th regular general meeting, 6 out of 8 director appointment proposals (5 inside directors, 3 outside directors) were rejected (0% approval), indicating strong shareholder opposition.
At the 19th extraordinary general meeting, all 4 appointment proposals (2 inside directors, 1 outside director, 1 auditor) were also rejected (approval rate 0.0-0.9%), reflecting distrust in management.
No dividends or shareholder returns for the past 3 years, no dividend policy or shareholder return policy established, leading to lack of dividend predictability.
Key governance items are inadequate: failure to give 4-week advance notice for shareholder meetings, lack of risk management internal control policy, no CEO succession plan, no internal audit support organization, etc.
Lack of outside director evaluation criteria, non-separation of board chair from CEO, no cumulative voting system, reducing board independence and transparency.
[AI Comprehensive Analysis]This disclosure shows that INBIOGEN's governance significantly falls short of best practice standards. The multiple rejections of director appointments highlight a conflict between shareholders and management, which could lead to increased business uncertainty and potential stock price decline. Investors should monitor governance improvement efforts and the establishment of shareholder return policies.